nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimipramine—SLC6A3—malignant glioma	0.638	1	CbGaD
Trimipramine—HTR1D—meninx—malignant glioma	0.0199	0.113	CbGeAlD
Trimipramine—HTR3A—fourth ventricle—malignant glioma	0.0193	0.11	CbGeAlD
Trimipramine—HTR1D—dura mater—malignant glioma	0.0183	0.104	CbGeAlD
Trimipramine—HTR2C—choroid plexus—malignant glioma	0.0154	0.0874	CbGeAlD
Trimipramine—HTR2A—choroid plexus—malignant glioma	0.00772	0.0439	CbGeAlD
Trimipramine—SLC6A3—telencephalic ventricle—malignant glioma	0.00466	0.0265	CbGeAlD
Trimipramine—HTR1D—telencephalic ventricle—malignant glioma	0.00455	0.0259	CbGeAlD
Trimipramine—HTR2C—telencephalic ventricle—malignant glioma	0.00451	0.0256	CbGeAlD
Trimipramine—HTR2A—cerebellar cortex—malignant glioma	0.00389	0.0221	CbGeAlD
Trimipramine—HTR1A—telencephalic ventricle—malignant glioma	0.00379	0.0216	CbGeAlD
Trimipramine—Tongue discolouration—Temozolomide—malignant glioma	0.00346	0.0503	CcSEcCtD
Trimipramine—DRD2—telencephalic ventricle—malignant glioma	0.00343	0.0195	CbGeAlD
Trimipramine—HTR2A—pons—malignant glioma	0.00275	0.0156	CbGeAlD
Trimipramine—HTR2A—vertebral column—malignant glioma	0.00273	0.0155	CbGeAlD
Trimipramine—HTR2A—telencephalic ventricle—malignant glioma	0.00226	0.0129	CbGeAlD
Trimipramine—HTR1D—blood vessel—malignant glioma	0.00225	0.0128	CbGeAlD
Trimipramine—Extrapyramidal disorder—Temozolomide—malignant glioma	0.00222	0.0323	CcSEcCtD
Trimipramine—Petechiae—Temozolomide—malignant glioma	0.00203	0.0296	CcSEcCtD
Trimipramine—HTR2A—pineal body—malignant glioma	0.00196	0.0111	CbGeAlD
Trimipramine—Coordination abnormal—Carmustine—malignant glioma	0.00176	0.0256	CcSEcCtD
Trimipramine—Coordination abnormal—Temozolomide—malignant glioma	0.0017	0.0248	CcSEcCtD
Trimipramine—Gynaecomastia—Carmustine—malignant glioma	0.00155	0.0225	CcSEcCtD
Trimipramine—HTR3A—brainstem—malignant glioma	0.00152	0.00862	CbGeAlD
Trimipramine—Vascular purpura—Temozolomide—malignant glioma	0.00136	0.0197	CcSEcCtD
Trimipramine—HTR3A—telencephalon—malignant glioma	0.00135	0.00765	CbGeAlD
Trimipramine—SLC6A3—brainstem—malignant glioma	0.00126	0.00717	CbGeAlD
Trimipramine—Purpura—Temozolomide—malignant glioma	0.00126	0.0183	CcSEcCtD
Trimipramine—HTR1D—brainstem—malignant glioma	0.00123	0.007	CbGeAlD
Trimipramine—HTR2C—brainstem—malignant glioma	0.00122	0.00693	CbGeAlD
Trimipramine—HTR2A—endothelium—malignant glioma	0.00121	0.0069	CbGeAlD
Trimipramine—Ataxia—Carmustine—malignant glioma	0.00118	0.0172	CcSEcCtD
Trimipramine—SLC6A4—brainstem—malignant glioma	0.00116	0.00657	CbGeAlD
Trimipramine—Ataxia—Temozolomide—malignant glioma	0.00114	0.0166	CcSEcCtD
Trimipramine—SLC6A3—telencephalon—malignant glioma	0.00112	0.00636	CbGeAlD
Trimipramine—HTR2A—blood vessel—malignant glioma	0.00112	0.00636	CbGeAlD
Trimipramine—HTR1D—telencephalon—malignant glioma	0.00109	0.00621	CbGeAlD
Trimipramine—HTR2C—telencephalon—malignant glioma	0.00108	0.00615	CbGeAlD
Trimipramine—Pancytopenia—Carmustine—malignant glioma	0.00103	0.015	CcSEcCtD
Trimipramine—HTR1A—brainstem—malignant glioma	0.00103	0.00583	CbGeAlD
Trimipramine—SLC6A4—telencephalon—malignant glioma	0.00103	0.00583	CbGeAlD
Trimipramine—SLC6A2—brainstem—malignant glioma	0.00102	0.00579	CbGeAlD
Trimipramine—Pancytopenia—Temozolomide—malignant glioma	0.000997	0.0145	CcSEcCtD
Trimipramine—Pollakiuria—Temozolomide—malignant glioma	0.00097	0.0141	CcSEcCtD
Trimipramine—Erectile dysfunction—Temozolomide—malignant glioma	0.000967	0.0141	CcSEcCtD
Trimipramine—Weight increased—Temozolomide—malignant glioma	0.000956	0.0139	CcSEcCtD
Trimipramine—Neuropathy peripheral—Carmustine—malignant glioma	0.00095	0.0138	CcSEcCtD
Trimipramine—ADRA1A—brainstem—malignant glioma	0.000946	0.00538	CbGeAlD
Trimipramine—Stomatitis—Carmustine—malignant glioma	0.000944	0.0137	CcSEcCtD
Trimipramine—Benzphetamine—POR—malignant glioma	0.000932	0.105	CrCbGaD
Trimipramine—DRD2—brainstem—malignant glioma	0.000928	0.00527	CbGeAlD
Trimipramine—Neuropathy peripheral—Temozolomide—malignant glioma	0.000918	0.0133	CcSEcCtD
Trimipramine—Stomatitis—Temozolomide—malignant glioma	0.000913	0.0133	CcSEcCtD
Trimipramine—HTR1A—telencephalon—malignant glioma	0.000911	0.00518	CbGeAlD
Trimipramine—SLC6A2—telencephalon—malignant glioma	0.000903	0.00513	CbGeAlD
Trimipramine—DRD2—retina—malignant glioma	0.000895	0.00509	CbGeAlD
Trimipramine—Hallucination—Carmustine—malignant glioma	0.000865	0.0126	CcSEcCtD
Trimipramine—Hypoaesthesia—Carmustine—malignant glioma	0.000865	0.0126	CcSEcCtD
Trimipramine—HTR2C—medulla oblongata—malignant glioma	0.00085	0.00483	CbGeAlD
Trimipramine—ADRA1B—central nervous system—malignant glioma	0.00085	0.00483	CbGeAlD
Trimipramine—ADRA1A—telencephalon—malignant glioma	0.00084	0.00477	CbGeAlD
Trimipramine—Hypoaesthesia—Temozolomide—malignant glioma	0.000836	0.0122	CcSEcCtD
Trimipramine—Hallucination—Temozolomide—malignant glioma	0.000836	0.0122	CcSEcCtD
Trimipramine—DRD2—telencephalon—malignant glioma	0.000823	0.00468	CbGeAlD
Trimipramine—Flushing—Carmustine—malignant glioma	0.000807	0.0117	CcSEcCtD
Trimipramine—SLC6A3—midbrain—malignant glioma	0.000804	0.00457	CbGeAlD
Trimipramine—HTR1D—midbrain—malignant glioma	0.000785	0.00446	CbGeAlD
Trimipramine—SLC6A3—spinal cord—malignant glioma	0.000785	0.00446	CbGeAlD
Trimipramine—Tinnitus—Temozolomide—malignant glioma	0.000784	0.0114	CcSEcCtD
Trimipramine—Flushing—Temozolomide—malignant glioma	0.00078	0.0113	CcSEcCtD
Trimipramine—HTR2C—midbrain—malignant glioma	0.000777	0.00442	CbGeAlD
Trimipramine—Arrhythmia—Carmustine—malignant glioma	0.000777	0.0113	CcSEcCtD
Trimipramine—Alopecia—Carmustine—malignant glioma	0.000769	0.0112	CcSEcCtD
Trimipramine—HTR3A—central nervous system—malignant glioma	0.000765	0.00435	CbGeAlD
Trimipramine—HTR2C—spinal cord—malignant glioma	0.000758	0.00431	CbGeAlD
Trimipramine—Alopecia—Temozolomide—malignant glioma	0.000743	0.0108	CcSEcCtD
Trimipramine—Amitriptyline—NTRK2—malignant glioma	0.00074	0.0831	CrCbGaD
Trimipramine—SLC6A4—midbrain—malignant glioma	0.000737	0.00419	CbGeAlD
Trimipramine—ABCB1—blood vessel—malignant glioma	0.000733	0.00417	CbGeAlD
Trimipramine—SLC6A4—spinal cord—malignant glioma	0.000719	0.00409	CbGeAlD
Trimipramine—Dysgeusia—Temozolomide—malignant glioma	0.000716	0.0104	CcSEcCtD
Trimipramine—Vision blurred—Carmustine—malignant glioma	0.000713	0.0104	CcSEcCtD
Trimipramine—SLC6A2—medulla oblongata—malignant glioma	0.00071	0.00403	CbGeAlD
Trimipramine—Tremor—Carmustine—malignant glioma	0.000709	0.0103	CcSEcCtD
Trimipramine—Agitation—Carmustine—malignant glioma	0.000696	0.0101	CcSEcCtD
Trimipramine—Vision blurred—Temozolomide—malignant glioma	0.000689	0.01	CcSEcCtD
Trimipramine—Tremor—Temozolomide—malignant glioma	0.000685	0.00996	CcSEcCtD
Trimipramine—Ill-defined disorder—Temozolomide—malignant glioma	0.000679	0.00987	CcSEcCtD
Trimipramine—ADRA1B—brain—malignant glioma	0.000675	0.00383	CbGeAlD
Trimipramine—Agitation—Temozolomide—malignant glioma	0.000672	0.00977	CcSEcCtD
Trimipramine—HTR2A—embryo—malignant glioma	0.000668	0.00379	CbGeAlD
Trimipramine—Malaise—Temozolomide—malignant glioma	0.00066	0.00959	CcSEcCtD
Trimipramine—Convulsion—Carmustine—malignant glioma	0.000656	0.00953	CcSEcCtD
Trimipramine—HTR1A—midbrain—malignant glioma	0.000654	0.00372	CbGeAlD
Trimipramine—Hypertension—Carmustine—malignant glioma	0.000654	0.0095	CcSEcCtD
Trimipramine—HRH1—telencephalon—malignant glioma	0.00065	0.00369	CbGeAlD
Trimipramine—Palpitations—Temozolomide—malignant glioma	0.000647	0.0094	CcSEcCtD
Trimipramine—Anxiety—Carmustine—malignant glioma	0.000642	0.00933	CcSEcCtD
Trimipramine—ADRA2A—telencephalon—malignant glioma	0.000639	0.00363	CbGeAlD
Trimipramine—HTR1A—spinal cord—malignant glioma	0.000638	0.00363	CbGeAlD
Trimipramine—SLC6A3—central nervous system—malignant glioma	0.000636	0.00362	CbGeAlD
Trimipramine—Convulsion—Temozolomide—malignant glioma	0.000634	0.00921	CcSEcCtD
Trimipramine—Hypertension—Temozolomide—malignant glioma	0.000632	0.00918	CcSEcCtD
Trimipramine—Confusional state—Carmustine—malignant glioma	0.000623	0.00905	CcSEcCtD
Trimipramine—SLC6A3—cerebellum—malignant glioma	0.000622	0.00354	CbGeAlD
Trimipramine—HTR1D—central nervous system—malignant glioma	0.000621	0.00353	CbGeAlD
Trimipramine—Anxiety—Temozolomide—malignant glioma	0.000621	0.00902	CcSEcCtD
Trimipramine—Oedema—Carmustine—malignant glioma	0.000618	0.00898	CcSEcCtD
Trimipramine—Discomfort—Temozolomide—malignant glioma	0.000615	0.00894	CcSEcCtD
Trimipramine—HTR2C—central nervous system—malignant glioma	0.000615	0.0035	CbGeAlD
Trimipramine—HTR2A—brainstem—malignant glioma	0.000612	0.00348	CbGeAlD
Trimipramine—Dry mouth—Temozolomide—malignant glioma	0.000609	0.00885	CcSEcCtD
Trimipramine—HTR3A—brain—malignant glioma	0.000607	0.00345	CbGeAlD
Trimipramine—Thrombocytopenia—Carmustine—malignant glioma	0.000605	0.00879	CcSEcCtD
Trimipramine—Tachycardia—Carmustine—malignant glioma	0.000603	0.00876	CcSEcCtD
Trimipramine—Confusional state—Temozolomide—malignant glioma	0.000602	0.00875	CcSEcCtD
Trimipramine—Oedema—Temozolomide—malignant glioma	0.000597	0.00868	CcSEcCtD
Trimipramine—DRD2—midbrain—malignant glioma	0.000591	0.00336	CbGeAlD
Trimipramine—HTR2A—retina—malignant glioma	0.00059	0.00335	CbGeAlD
Trimipramine—Anorexia—Carmustine—malignant glioma	0.000589	0.00856	CcSEcCtD
Trimipramine—Thrombocytopenia—Temozolomide—malignant glioma	0.000585	0.0085	CcSEcCtD
Trimipramine—SLC6A4—central nervous system—malignant glioma	0.000583	0.00331	CbGeAlD
Trimipramine—Hypotension—Carmustine—malignant glioma	0.000577	0.00839	CcSEcCtD
Trimipramine—Anorexia—Temozolomide—malignant glioma	0.000569	0.00827	CcSEcCtD
Trimipramine—Insomnia—Carmustine—malignant glioma	0.000559	0.00812	CcSEcCtD
Trimipramine—Epinastine—CYP2B6—malignant glioma	0.000558	0.0627	CrCbGaD
Trimipramine—CYP2D6—brainstem—malignant glioma	0.000557	0.00317	CbGeAlD
Trimipramine—Paraesthesia—Carmustine—malignant glioma	0.000555	0.00806	CcSEcCtD
Trimipramine—Somnolence—Carmustine—malignant glioma	0.000549	0.00798	CcSEcCtD
Trimipramine—HTR2A—telencephalon—malignant glioma	0.000543	0.00309	CbGeAlD
Trimipramine—Insomnia—Temozolomide—malignant glioma	0.00054	0.00785	CcSEcCtD
Trimipramine—Decreased appetite—Carmustine—malignant glioma	0.000537	0.00781	CcSEcCtD
Trimipramine—Paraesthesia—Temozolomide—malignant glioma	0.000536	0.00779	CcSEcCtD
Trimipramine—Somnolence—Temozolomide—malignant glioma	0.000531	0.00771	CcSEcCtD
Trimipramine—Constipation—Carmustine—malignant glioma	0.000528	0.00768	CcSEcCtD
Trimipramine—Dyspepsia—Temozolomide—malignant glioma	0.000526	0.00764	CcSEcCtD
Trimipramine—Decreased appetite—Temozolomide—malignant glioma	0.000519	0.00754	CcSEcCtD
Trimipramine—HTR1A—central nervous system—malignant glioma	0.000518	0.00294	CbGeAlD
Trimipramine—Fatigue—Temozolomide—malignant glioma	0.000515	0.00748	CcSEcCtD
Trimipramine—SLC6A2—central nervous system—malignant glioma	0.000513	0.00292	CbGeAlD
Trimipramine—Constipation—Temozolomide—malignant glioma	0.000511	0.00742	CcSEcCtD
Trimipramine—Feeling abnormal—Carmustine—malignant glioma	0.000509	0.0074	CcSEcCtD
Trimipramine—HTR1A—cerebellum—malignant glioma	0.000506	0.00288	CbGeAlD
Trimipramine—SLC6A3—brain—malignant glioma	0.000505	0.00287	CbGeAlD
Trimipramine—ADRA2A—medulla oblongata—malignant glioma	0.000502	0.00285	CbGeAlD
Trimipramine—CYP2D6—telencephalon—malignant glioma	0.000495	0.00281	CbGeAlD
Trimipramine—HTR1D—brain—malignant glioma	0.000493	0.0028	CbGeAlD
Trimipramine—Feeling abnormal—Temozolomide—malignant glioma	0.000492	0.00715	CcSEcCtD
Trimipramine—HTR2C—brain—malignant glioma	0.000488	0.00278	CbGeAlD
Trimipramine—Abdominal pain—Carmustine—malignant glioma	0.000488	0.0071	CcSEcCtD
Trimipramine—Body temperature increased—Carmustine—malignant glioma	0.000488	0.0071	CcSEcCtD
Trimipramine—ADRA1A—central nervous system—malignant glioma	0.000477	0.00271	CbGeAlD
Trimipramine—Urticaria—Temozolomide—malignant glioma	0.000474	0.00689	CcSEcCtD
Trimipramine—Body temperature increased—Temozolomide—malignant glioma	0.000472	0.00686	CcSEcCtD
Trimipramine—Abdominal pain—Temozolomide—malignant glioma	0.000472	0.00686	CcSEcCtD
Trimipramine—DRD2—central nervous system—malignant glioma	0.000468	0.00266	CbGeAlD
Trimipramine—ADRA1A—cerebellum—malignant glioma	0.000467	0.00265	CbGeAlD
Trimipramine—SLC6A4—brain—malignant glioma	0.000463	0.00263	CbGeAlD
Trimipramine—ADRA2A—midbrain—malignant glioma	0.000459	0.00261	CbGeAlD
Trimipramine—DRD2—cerebellum—malignant glioma	0.000457	0.0026	CbGeAlD
Trimipramine—Amitriptyline—NTRK1—malignant glioma	0.000457	0.0513	CrCbGaD
Trimipramine—ADRA2A—spinal cord—malignant glioma	0.000447	0.00254	CbGeAlD
Trimipramine—Asthenia—Carmustine—malignant glioma	0.000443	0.00644	CcSEcCtD
Trimipramine—ABCB1—embryo—malignant glioma	0.000438	0.00249	CbGeAlD
Trimipramine—Asthenia—Temozolomide—malignant glioma	0.000428	0.00623	CcSEcCtD
Trimipramine—HTR2A—medulla oblongata—malignant glioma	0.000427	0.00242	CbGeAlD
Trimipramine—Diarrhoea—Carmustine—malignant glioma	0.000423	0.00614	CcSEcCtD
Trimipramine—Pruritus—Temozolomide—malignant glioma	0.000422	0.00614	CcSEcCtD
Trimipramine—Ethopropazine—BCHE—malignant glioma	0.000418	0.047	CrCbGaD
Trimipramine—HTR1A—brain—malignant glioma	0.000411	0.00234	CbGeAlD
Trimipramine—Dizziness—Carmustine—malignant glioma	0.000409	0.00594	CcSEcCtD
Trimipramine—Diarrhoea—Temozolomide—malignant glioma	0.000409	0.00594	CcSEcCtD
Trimipramine—SLC6A2—brain—malignant glioma	0.000408	0.00232	CbGeAlD
Trimipramine—Dizziness—Temozolomide—malignant glioma	0.000395	0.00574	CcSEcCtD
Trimipramine—Vomiting—Carmustine—malignant glioma	0.000393	0.00571	CcSEcCtD
Trimipramine—HTR2A—midbrain—malignant glioma	0.00039	0.00222	CbGeAlD
Trimipramine—Rash—Carmustine—malignant glioma	0.00039	0.00566	CcSEcCtD
Trimipramine—Dermatitis—Carmustine—malignant glioma	0.000389	0.00566	CcSEcCtD
Trimipramine—Headache—Carmustine—malignant glioma	0.000387	0.00563	CcSEcCtD
Trimipramine—ABCB1—retina—malignant glioma	0.000387	0.0022	CbGeAlD
Trimipramine—HTR2A—spinal cord—malignant glioma	0.00038	0.00216	CbGeAlD
Trimipramine—Vomiting—Temozolomide—malignant glioma	0.00038	0.00552	CcSEcCtD
Trimipramine—ADRA1A—brain—malignant glioma	0.000379	0.00215	CbGeAlD
Trimipramine—Rash—Temozolomide—malignant glioma	0.000376	0.00547	CcSEcCtD
Trimipramine—Dermatitis—Temozolomide—malignant glioma	0.000376	0.00547	CcSEcCtD
Trimipramine—Headache—Temozolomide—malignant glioma	0.000374	0.00544	CcSEcCtD
Trimipramine—DRD2—brain—malignant glioma	0.000371	0.00211	CbGeAlD
Trimipramine—HRH1—central nervous system—malignant glioma	0.00037	0.0021	CbGeAlD
Trimipramine—Nausea—Carmustine—malignant glioma	0.000367	0.00533	CcSEcCtD
Trimipramine—ADRA2A—central nervous system—malignant glioma	0.000363	0.00206	CbGeAlD
Trimipramine—Diphenhydramine—CYP2C18—malignant glioma	0.000359	0.0404	CrCbGaD
Trimipramine—ABCB1—telencephalon—malignant glioma	0.000356	0.00202	CbGeAlD
Trimipramine—ADRA2A—cerebellum—malignant glioma	0.000355	0.00202	CbGeAlD
Trimipramine—Nausea—Temozolomide—malignant glioma	0.000355	0.00515	CcSEcCtD
Trimipramine—Clomipramine—GSTP1—malignant glioma	0.000351	0.0395	CrCbGaD
Trimipramine—Carbamazepine—CYP2B6—malignant glioma	0.00035	0.0394	CrCbGaD
Trimipramine—Methadone—CYP2C18—malignant glioma	0.000347	0.039	CrCbGaD
Trimipramine—Benzphetamine—CYP2B6—malignant glioma	0.000333	0.0374	CrCbGaD
Trimipramine—Mianserin—CYP2B6—malignant glioma	0.000323	0.0363	CrCbGaD
Trimipramine—Desipramine—CYP2C18—malignant glioma	0.00032	0.036	CrCbGaD
Trimipramine—HTR2A—central nervous system—malignant glioma	0.000309	0.00175	CbGeAlD
Trimipramine—HTR2A—cerebellum—malignant glioma	0.000302	0.00171	CbGeAlD
Trimipramine—HRH1—brain—malignant glioma	0.000293	0.00167	CbGeAlD
Trimipramine—ADRA2A—brain—malignant glioma	0.000288	0.00164	CbGeAlD
Trimipramine—CYP3A4—central nervous system—malignant glioma	0.000286	0.00162	CbGeAlD
Trimipramine—Benzphetamine—SLC6A3—malignant glioma	0.000284	0.0319	CrCbGaD
Trimipramine—CYP2D6—central nervous system—malignant glioma	0.000281	0.0016	CbGeAlD
Trimipramine—ABCB1—medulla oblongata—malignant glioma	0.00028	0.00159	CbGeAlD
Trimipramine—Mianserin—SLC6A3—malignant glioma	0.000275	0.0309	CrCbGaD
Trimipramine—CYP2D6—cerebellum—malignant glioma	0.000275	0.00156	CbGeAlD
Trimipramine—Imipramine—CYP2C18—malignant glioma	0.000271	0.0305	CrCbGaD
Trimipramine—Diphenhydramine—CYP2B6—malignant glioma	0.000267	0.03	CrCbGaD
Trimipramine—Promethazine—CYP2B6—malignant glioma	0.000262	0.0294	CrCbGaD
Trimipramine—Methadone—CYP2B6—malignant glioma	0.000258	0.0289	CrCbGaD
Trimipramine—ABCB1—midbrain—malignant glioma	0.000256	0.00145	CbGeAlD
Trimipramine—Orphenadrine—CYP2B6—malignant glioma	0.000252	0.0283	CrCbGaD
Trimipramine—ABCB1—spinal cord—malignant glioma	0.000249	0.00142	CbGeAlD
Trimipramine—HTR2A—brain—malignant glioma	0.000245	0.00139	CbGeAlD
Trimipramine—Desipramine—CYP2B6—malignant glioma	0.000238	0.0267	CrCbGaD
Trimipramine—CYP2D6—brain—malignant glioma	0.000223	0.00127	CbGeAlD
Trimipramine—Desipramine—SLC6A3—malignant glioma	0.000202	0.0227	CrCbGaD
Trimipramine—ABCB1—central nervous system—malignant glioma	0.000202	0.00115	CbGeAlD
Trimipramine—Imipramine—CYP2B6—malignant glioma	0.000201	0.0226	CrCbGaD
Trimipramine—Amitriptyline—CYP2B6—malignant glioma	0.0002	0.0225	CrCbGaD
Trimipramine—ABCB1—cerebellum—malignant glioma	0.000198	0.00112	CbGeAlD
Trimipramine—Nortriptyline—PTGS1—malignant glioma	0.00019	0.0213	CrCbGaD
Trimipramine—Diphenhydramine—PTGS1—malignant glioma	0.000176	0.0197	CrCbGaD
Trimipramine—Imipramine—SLC6A3—malignant glioma	0.000172	0.0193	CrCbGaD
Trimipramine—Chlorpromazine—BCHE—malignant glioma	0.000165	0.0186	CrCbGaD
Trimipramine—ABCB1—brain—malignant glioma	0.000161	0.000913	CbGeAlD
Trimipramine—ADRA2B—Signaling Pathways—CXCL8—malignant glioma	7.45e-06	6.86e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—PIK3CB—malignant glioma	7.44e-06	6.86e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—PIK3CD—malignant glioma	7.42e-06	6.83e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—PIK3CD—malignant glioma	7.4e-06	6.82e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling by GPCR—KRAS—malignant glioma	7.38e-06	6.8e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling by GPCR—PIK3CA—malignant glioma	7.35e-06	6.77e-05	CbGpPWpGaD
Trimipramine—HTR2A—GPCR downstream signaling—PIK3CA—malignant glioma	7.34e-06	6.77e-05	CbGpPWpGaD
Trimipramine—HRH1—GPCR downstream signaling—PIK3CA—malignant glioma	7.33e-06	6.75e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—MDM2—malignant glioma	7.32e-06	6.75e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—RAF1—malignant glioma	7.3e-06	6.72e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—PIK3CD—malignant glioma	7.26e-06	6.69e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—KRAS—malignant glioma	7.26e-06	6.69e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—KRAS—malignant glioma	7.24e-06	6.68e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—ERBB2—malignant glioma	7.22e-06	6.65e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—FGF2—malignant glioma	7.22e-06	6.65e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—BRAF—malignant glioma	7.21e-06	6.65e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—MYC—malignant glioma	7.2e-06	6.64e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—BCHE—malignant glioma	7.2e-06	6.64e-05	CbGpPWpGaD
Trimipramine—ADRA2B—GPCR downstream signaling—AKT1—malignant glioma	7.19e-06	6.63e-05	CbGpPWpGaD
Trimipramine—ADRA1A—GPCR downstream signaling—PIK3CA—malignant glioma	7.19e-06	6.63e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—CXCL8—malignant glioma	7.19e-06	6.62e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—CXCL8—malignant glioma	7.15e-06	6.59e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—CAV1—malignant glioma	7.14e-06	6.58e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—CASP3—malignant glioma	7.13e-06	6.57e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—PIK3CB—malignant glioma	7.12e-06	6.57e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—IL2—malignant glioma	7.12e-06	6.56e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—SLC5A5—malignant glioma	7.11e-06	6.55e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—KRAS—malignant glioma	7.11e-06	6.55e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—FGF2—malignant glioma	7.1e-06	6.54e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—FGF2—malignant glioma	7.08e-06	6.53e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—EGFR—malignant glioma	7.04e-06	6.49e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—PIK3CB—malignant glioma	7.03e-06	6.48e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—AKT2—malignant glioma	7.02e-06	6.47e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—EGFR—malignant glioma	6.99e-06	6.44e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—PTGS2—malignant glioma	6.97e-06	6.42e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—CAV1—malignant glioma	6.97e-06	6.42e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—FGF2—malignant glioma	6.95e-06	6.41e-05	CbGpPWpGaD
Trimipramine—HTR1A—GPCR downstream signaling—AKT1—malignant glioma	6.95e-06	6.4e-05	CbGpPWpGaD
Trimipramine—HTR2C—GPCR downstream signaling—AKT1—malignant glioma	6.91e-06	6.37e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—CASP3—malignant glioma	6.88e-06	6.34e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—IL2—malignant glioma	6.87e-06	6.33e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—CXCL8—malignant glioma	6.85e-06	6.31e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—CASP3—malignant glioma	6.85e-06	6.31e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—IL2—malignant glioma	6.84e-06	6.3e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	6.82e-06	6.28e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling by GPCR—PIK3CA—malignant glioma	6.78e-06	6.25e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MDM2—malignant glioma	6.75e-06	6.22e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—PIK3CD—malignant glioma	6.75e-06	6.22e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—MMP9—malignant glioma	6.74e-06	6.21e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—RAF1—malignant glioma	6.73e-06	6.2e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—PTEN—malignant glioma	6.7e-06	6.17e-05	CbGpPWpGaD
Trimipramine—ADRA2A—GPCR downstream signaling—PIK3CA—malignant glioma	6.68e-06	6.16e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—PIK3CA—malignant glioma	6.67e-06	6.15e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—ERBB2—malignant glioma	6.66e-06	6.13e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—PIK3CA—malignant glioma	6.66e-06	6.13e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—KRAS—malignant glioma	6.66e-06	6.13e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MDM2—malignant glioma	6.64e-06	6.12e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MDM2—malignant glioma	6.63e-06	6.11e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—RAF1—malignant glioma	6.62e-06	6.1e-05	CbGpPWpGaD
Trimipramine—ADRA1B—GPCR downstream signaling—AKT1—malignant glioma	6.61e-06	6.09e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—RAF1—malignant glioma	6.61e-06	6.09e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—KRAS—malignant glioma	6.6e-06	6.09e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—PIK3CB—malignant glioma	6.57e-06	6.05e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—CAV1—malignant glioma	6.57e-06	6.05e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—CASP3—malignant glioma	6.55e-06	6.04e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—ERBB2—malignant glioma	6.55e-06	6.04e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—IL2—malignant glioma	6.54e-06	6.03e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—ERBB2—malignant glioma	6.54e-06	6.02e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling by GPCR—AKT1—malignant glioma	6.53e-06	6.02e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—PIK3CA—malignant glioma	6.53e-06	6.02e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—CAV1—malignant glioma	6.51e-06	6e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MDM2—malignant glioma	6.5e-06	5.99e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—MMP9—malignant glioma	6.5e-06	5.99e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PIK3CG—malignant glioma	6.5e-06	5.99e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—RAF1—malignant glioma	6.48e-06	5.97e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—MMP9—malignant glioma	6.47e-06	5.96e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—PTEN—malignant glioma	6.46e-06	5.96e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—PIK3CB—malignant glioma	6.46e-06	5.96e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—FGF2—malignant glioma	6.46e-06	5.95e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—PIK3CB—malignant glioma	6.45e-06	5.94e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—PTEN—malignant glioma	6.43e-06	5.93e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—ERBB2—malignant glioma	6.41e-06	5.91e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PIK3CG—malignant glioma	6.35e-06	5.85e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—PIK3CB—malignant glioma	6.33e-06	5.83e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CXCL8—malignant glioma	6.31e-06	5.82e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling by GPCR—AKT1—malignant glioma	6.31e-06	5.81e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PPARG—malignant glioma	6.28e-06	5.78e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling by GPCR—AKT1—malignant glioma	6.27e-06	5.78e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	6.22e-06	5.73e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CXCL8—malignant glioma	6.21e-06	5.72e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CXCL8—malignant glioma	6.2e-06	5.71e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—MMP9—malignant glioma	6.19e-06	5.71e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—PTEN—malignant glioma	6.16e-06	5.67e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PPARG—malignant glioma	6.12e-06	5.64e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—PIK3CA—malignant glioma	6.11e-06	5.63e-05	CbGpPWpGaD
Trimipramine—DRD2—GPCR downstream signaling—AKT1—malignant glioma	6.1e-06	5.62e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CXCL8—malignant glioma	6.08e-06	5.6e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—PTEN—malignant glioma	6.08e-06	5.6e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—PIK3CA—malignant glioma	6.07e-06	5.59e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—VEGFA—malignant glioma	6.05e-06	5.57e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MDM2—malignant glioma	6.04e-06	5.57e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CASP3—malignant glioma	6.04e-06	5.57e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—IL2—malignant glioma	6.03e-06	5.56e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—RAF1—malignant glioma	6.02e-06	5.55e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling by GPCR—AKT1—malignant glioma	6.01e-06	5.53e-05	CbGpPWpGaD
Trimipramine—HTR2A—GPCR downstream signaling—AKT1—malignant glioma	6e-06	5.53e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—STAT3—malignant glioma	5.99e-06	5.52e-05	CbGpPWpGaD
Trimipramine—HRH1—GPCR downstream signaling—AKT1—malignant glioma	5.99e-06	5.52e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PIK3CG—malignant glioma	5.98e-06	5.51e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—ERBB2—malignant glioma	5.96e-06	5.49e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CASP3—malignant glioma	5.94e-06	5.48e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—IL2—malignant glioma	5.94e-06	5.47e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CASP3—malignant glioma	5.93e-06	5.47e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PIK3CG—malignant glioma	5.93e-06	5.46e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—IL2—malignant glioma	5.92e-06	5.46e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—TP53—malignant glioma	5.92e-06	5.45e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—PIK3CB—malignant glioma	5.88e-06	5.42e-05	CbGpPWpGaD
Trimipramine—ADRA1A—GPCR downstream signaling—AKT1—malignant glioma	5.88e-06	5.41e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—VEGFA—malignant glioma	5.84e-06	5.38e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CASP3—malignant glioma	5.82e-06	5.36e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—IL2—malignant glioma	5.81e-06	5.36e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—VEGFA—malignant glioma	5.81e-06	5.35e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—STAT3—malignant glioma	5.78e-06	5.33e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PPARG—malignant glioma	5.77e-06	5.32e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—STAT3—malignant glioma	5.75e-06	5.3e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—GSTP1—malignant glioma	5.73e-06	5.28e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PPARG—malignant glioma	5.72e-06	5.27e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PIK3CD—malignant glioma	5.72e-06	5.27e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MMP9—malignant glioma	5.71e-06	5.26e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—PTEN—malignant glioma	5.68e-06	5.23e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CXCL8—malignant glioma	5.65e-06	5.21e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MMP9—malignant glioma	5.62e-06	5.18e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MMP9—malignant glioma	5.61e-06	5.17e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—PTEN—malignant glioma	5.59e-06	5.15e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PIK3CD—malignant glioma	5.58e-06	5.14e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—CAT—malignant glioma	5.58e-06	5.14e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—PTEN—malignant glioma	5.57e-06	5.14e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—MYC—malignant glioma	5.57e-06	5.13e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—VEGFA—malignant glioma	5.56e-06	5.12e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling by GPCR—AKT1—malignant glioma	5.54e-06	5.1e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—STAT3—malignant glioma	5.51e-06	5.07e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MMP9—malignant glioma	5.5e-06	5.07e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—PTEN—malignant glioma	5.47e-06	5.04e-05	CbGpPWpGaD
Trimipramine—ADRA2A—GPCR downstream signaling—AKT1—malignant glioma	5.46e-06	5.03e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—AKT1—malignant glioma	5.45e-06	5.02e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—EGFR—malignant glioma	5.44e-06	5.02e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—AKT1—malignant glioma	5.44e-06	5.01e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CASP3—malignant glioma	5.41e-06	4.98e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—IL2—malignant glioma	5.4e-06	4.98e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—MYC—malignant glioma	5.37e-06	4.95e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—MYC—malignant glioma	5.34e-06	4.93e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—AKT1—malignant glioma	5.34e-06	4.92e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—NCOR1—malignant glioma	5.27e-06	4.85e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PIK3CD—malignant glioma	5.26e-06	4.84e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—EGFR—malignant glioma	5.25e-06	4.84e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—EGFR—malignant glioma	5.23e-06	4.82e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PIK3CD—malignant glioma	5.21e-06	4.8e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—KRAS—malignant glioma	5.14e-06	4.74e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—VEGFA—malignant glioma	5.13e-06	4.72e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—MYC—malignant glioma	5.12e-06	4.71e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MMP9—malignant glioma	5.11e-06	4.71e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—PTEN—malignant glioma	5.08e-06	4.68e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—STAT3—malignant glioma	5.08e-06	4.68e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—VEGFA—malignant glioma	5.04e-06	4.65e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—VEGFA—malignant glioma	5.03e-06	4.64e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—EGFR—malignant glioma	5e-06	4.61e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—AKT1—malignant glioma	4.99e-06	4.6e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—STAT3—malignant glioma	4.99e-06	4.6e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—STAT3—malignant glioma	4.98e-06	4.59e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PIK3CB—malignant glioma	4.98e-06	4.59e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—KRAS—malignant glioma	4.96e-06	4.57e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—AKT1—malignant glioma	4.96e-06	4.57e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—VEGFA—malignant glioma	4.94e-06	4.55e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—KRAS—malignant glioma	4.94e-06	4.55e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PTGS2—malignant glioma	4.94e-06	4.55e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—STAT3—malignant glioma	4.89e-06	4.51e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PIK3CB—malignant glioma	4.86e-06	4.48e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PTGS2—malignant glioma	4.82e-06	4.44e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—KRAS—malignant glioma	4.73e-06	4.36e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—PIK3CA—malignant glioma	4.72e-06	4.35e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MYC—malignant glioma	4.72e-06	4.35e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MYC—malignant glioma	4.64e-06	4.28e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MYC—malignant glioma	4.63e-06	4.27e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—EGFR—malignant glioma	4.61e-06	4.25e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—VEGFA—malignant glioma	4.59e-06	4.23e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PIK3CB—malignant glioma	4.58e-06	4.22e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—TP53—malignant glioma	4.57e-06	4.21e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—PIK3CA—malignant glioma	4.56e-06	4.2e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MYC—malignant glioma	4.54e-06	4.19e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—STAT3—malignant glioma	4.54e-06	4.19e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PIK3CB—malignant glioma	4.54e-06	4.19e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PTGS2—malignant glioma	4.54e-06	4.18e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—EGFR—malignant glioma	4.54e-06	4.18e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—PIK3CA—malignant glioma	4.54e-06	4.18e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—EGFR—malignant glioma	4.53e-06	4.17e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PTGS2—malignant glioma	4.5e-06	4.15e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—EGFR—malignant glioma	4.45e-06	4.1e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—TP53—malignant glioma	4.41e-06	4.07e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—TP53—malignant glioma	4.39e-06	4.04e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—KRAS—malignant glioma	4.36e-06	4.02e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—PIK3CA—malignant glioma	4.34e-06	4e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PTEN—malignant glioma	4.31e-06	3.97e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—CAV1—malignant glioma	4.29e-06	3.96e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—KRAS—malignant glioma	4.29e-06	3.95e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—PIK3CA—malignant glioma	4.29e-06	3.95e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—KRAS—malignant glioma	4.28e-06	3.94e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MYC—malignant glioma	4.22e-06	3.89e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PTEN—malignant glioma	4.2e-06	3.87e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—TP53—malignant glioma	4.2e-06	3.87e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—KRAS—malignant glioma	4.2e-06	3.87e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—EGFR—malignant glioma	4.13e-06	3.81e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—PIK3CA—malignant glioma	4e-06	3.69e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PTEN—malignant glioma	3.96e-06	3.65e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—PIK3CA—malignant glioma	3.94e-06	3.63e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—PIK3CA—malignant glioma	3.93e-06	3.62e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PTEN—malignant glioma	3.93e-06	3.62e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PIK3CG—malignant glioma	3.91e-06	3.6e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—KRAS—malignant glioma	3.9e-06	3.6e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—TP53—malignant glioma	3.87e-06	3.57e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—AKT1—malignant glioma	3.86e-06	3.56e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—PIK3CA—malignant glioma	3.86e-06	3.55e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—TP53—malignant glioma	3.81e-06	3.51e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—TP53—malignant glioma	3.8e-06	3.5e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PPARG—malignant glioma	3.77e-06	3.48e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—TP53—malignant glioma	3.73e-06	3.44e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—AKT1—malignant glioma	3.73e-06	3.43e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—AKT1—malignant glioma	3.71e-06	3.42e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—PIK3CA—malignant glioma	3.58e-06	3.3e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—AKT1—malignant glioma	3.55e-06	3.27e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—AKT1—malignant glioma	3.5e-06	3.23e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—TP53—malignant glioma	3.47e-06	3.2e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PIK3CD—malignant glioma	3.44e-06	3.17e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—AKT1—malignant glioma	3.27e-06	3.01e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—AKT1—malignant glioma	3.22e-06	2.97e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—AKT1—malignant glioma	3.21e-06	2.96e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—AKT1—malignant glioma	3.15e-06	2.9e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PIK3CA—malignant glioma	3.04e-06	2.8e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PIK3CB—malignant glioma	3e-06	2.76e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PTGS2—malignant glioma	2.97e-06	2.74e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PIK3CA—malignant glioma	2.96e-06	2.73e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—AKT1—malignant glioma	2.93e-06	2.7e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PIK3CA—malignant glioma	2.79e-06	2.57e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PIK3CA—malignant glioma	2.77e-06	2.55e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PTEN—malignant glioma	2.59e-06	2.39e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—AKT1—malignant glioma	2.48e-06	2.29e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—AKT1—malignant glioma	2.42e-06	2.23e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—AKT1—malignant glioma	2.28e-06	2.1e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—AKT1—malignant glioma	2.26e-06	2.08e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.83e-06	1.68e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—AKT1—malignant glioma	1.49e-06	1.37e-05	CbGpPWpGaD
